RUNX1 and acute myeloid leukemia: Within the RELAZA2 trial, AML and high-risk MDS patients in CR prospectively received pre-emptive azacitidine after developing MRD-positive disease defined as either decline of CD34-chimerism <80% or >1% burden of RUNX1/RUNX1T1 or NPM1 mutation levels.